BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 18767126)

  • 1. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
    Yaneva R; Springer S; Zacharias M
    Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational flexibility of the MHC class I alpha1-alpha2 domain in peptide bound and free states: a molecular dynamics simulation study.
    Zacharias M; Springer S
    Biophys J; 2004 Oct; 87(4):2203-14. PubMed ID: 15454423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential tapasin dependence of MHC class I molecules correlates with conformational changes upon peptide dissociation: a molecular dynamics simulation study.
    Sieker F; Straatsma TP; Springer S; Zacharias M
    Mol Immunol; 2008 Aug; 45(14):3714-22. PubMed ID: 18639935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell recognition of flanking residues of murine invariant chain-derived CLIP peptide bound to MHC class II.
    Naujokas MF; Southwood S; Mathies SJ; Appella E; Sette A; Miller J
    Cell Immunol; 1998 Aug; 188(1):49-54. PubMed ID: 9743557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
    Verreck FA; Fargeas CA; Hämmerling GJ
    Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner.
    Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T
    J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
    Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
    J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
    Thayer WP; Ignatowicz L; Weber DA; Jensen PE
    J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
    J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
    Liang MN; Lee C; Xia Y; McConnell HM
    Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diminished class II-associated Ii peptide binding to the juvenile dermatomyositis HLA-DQ alpha 1*0501/DQ beta 1*0301 molecule.
    Reed AM; Collins EJ; Shock LP; Klapper DG; Frelinger JA
    J Immunol; 1997 Dec; 159(12):6260-5. PubMed ID: 9550430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular modeling of an antigenic complex between a viral peptide and a class I major histocompatibility glycoprotein.
    Rognan D; Reddehase MJ; Koszinowski UH; Folkers G
    Proteins; 1992 May; 13(1):70-85. PubMed ID: 1594579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
    Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
    J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
    Stumptner P; Benaroch P
    EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes at the floor of the peptide-binding groove induce a strong preference for proline at position 3 of the bound peptide: molecular dynamics simulations of HLA-A*0217.
    Toh H; Savoie CJ; Kamikawaji N; Muta S; Sasazuki T; Kuhara S
    Biopolymers; 2000 Oct; 54(5):318-27. PubMed ID: 10935972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
    Xu M; Jackson R; Adams S; Humphreys RE
    Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
    Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
    Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.